Mati Therapeutics Inc.

Mati Therapeutics Inc. is a privately held ophthalmic drug delivery company headquartered in Austin, Texas. The company is developing a non-invasive sustained drug delivery platform aimed at treating ocular diseases, with a particular focus on glaucoma. Its core technology, the Evolute® Punctal Plug Delivery System, is designed to deliver medication continuously to the eye over an extended period, removing the need for patients or caregivers to administer eye drops. The Evolute® system builds on the well-established punctal plug, a small device traditionally used to block tear drainage in patients with dry eye syndrome. Mati's platform combines proprietary punctal plugs engineered to remain in place for a desired treatment duration with a proprietary drug delivery core that can be tailored to release a range of therapeutic agents over different time periods. The device is placed in the tear duct, or punctum, during a simple office procedure routinely performed by an ophthalmologist or optometrist, and is described as small, comfortable and cosmetically invisible. Mati is targeting several ophthalmic indications, including post-surgical pain and inflammation, glaucoma and ocular hypertension, allergy, and dry eye. The company's founders held senior leadership positions at Allergan, AMO, Abbott Laboratories and QLT Inc., bringing over a hundred years of combined ophthalmology experience. Robert (Bob) Butchofsky, the former President and CEO of QLT Inc., serves as Chief Executive Officer of Mati Therapeutics. Mati pursues a flexible partnership strategy, having demonstrated the ability to formulate different molecules for delivery through its punctal plug system. The company is exploring structures to introduce additional new chemical entities into its pipeline and to leverage that pipeline through regional strategic partnerships. As a private, development-stage company, Mati does not publicly disclose detailed financial information.

Mati Therapeutics Inc. is an ophthalmic drug delivery company headquartered in Austin, Texas. The company was founded by individuals who previously held senior leadership positions at Allergan, AMO, Abbott Laboratories and QLT Inc., collectively bringing over a hundred years of experience in ophthalmology. This founding team's background shaped Mati's strategic focus on sustained therapy delivery for ophthalmic disorders. A central figure in Mati's leadership is Robert (Bob) Butchofsky, who serves as Chief Executive Officer. Butchofsky previously served as President and CEO of QLT Inc., a publicly traded ophthalmology-focused pharmaceutical company. He joined QLT in 1998 as Associate Director, Ocular Marketing, and was appointed Vice President, Marketing and Sales Planning in September 2001. He was promoted to Senior Vice President, Marketing and Sales Planning in early 2005, responsible for marketing QLT's pharmaceutical products Visudyne® and Eligard®, managing significant corporate partnerships, corporate strategy development and investor relations. He served as interim CEO of QLT from September 2005, becoming CEO and a Board member in February 2006, continuing until August 2012. During his tenure, he refocused QLT on ophthalmology, divesting non-core assets including the generic dermatology business (2006), Aczone (2008), Atrigel (2008), the corporate headquarters building and land (2008) and Eligard (2009). He also led the acquisition of new technologies, including a synthetic retinoid program from Retinagenix for inherited retinal diseases and punctal plug drug delivery technology from ForSight Labs, and secured US commercial rights for Visudyne from Novartis. Before QLT, from June 1990 to August 1998, Butchofsky worked at Allergan Inc., building extensive experience with ocular pharmaceutical products and Botox®. Mati's core technology, the Evolute® Punctal Plug Drug Delivery System, builds upon the well-known punctal plug. Punctal plugs have traditionally been used to block tear drainage in patients with dry eye syndrome and the dry eye effects of various ocular surface diseases. Mati's objective is to complete development of the Evolute as a proprietary, minimally invasive drug delivery system that introduces a variety of therapeutic agents to the eye through controlled, sustained release to the tear film. The platform comprises multiple proprietary punctal plugs designed to be retained for the desired treatment duration, along with a proprietary drug delivery core that can be tailored to deliver a wide range of therapeutic agents over different time periods. The device is placed in the tear duct, or punctum, in a simple office procedure routinely performed by an ophthalmologist or optometrist. Mati is currently targeting the treatment of post-surgical pain and inflammation, glaucoma and ocular hypertension, allergy and dry eye. The company emphasizes the scale of the unmet need, noting that more than 1 billion people worldwide have vision impairment or blindness from potentially preventable or correctable causes, and that vision impairment is associated with lower quality of life and co-morbidities such as depression, anxiety and cognitive decline. Mati pursues a flexible partnership strategy, having demonstrated the ability to formulate different molecules for delivery through its punctal plug system, and is exploring structures to introduce additional new chemical entities into its pipeline and to leverage the pipeline through regional strategic partnerships.

• Mati Therapeutics is headquartered in Austin, Texas, and is developing the Evolute® Punctal Plug Drug Delivery System.

• Robert Butchofsky, former President and CEO of QLT Inc., serves as Chief Executive Officer of Mati Therapeutics.

Development-stage ophthalmic drug delivery company focused on non-invasive, sustained-release therapies for glaucoma and other ocular diseases.

• Evolute® Punctal Plug Drug Delivery System

  A small, comfortable and cosmetically invisible punctal plug placed in the tear duct that automatically delivers medication to the eye for an extended period, eliminating the need for eye drops.

1. 1Corporate Overview | Mati Therapeuticsmatitherapeutics.com
2. 2Leadership Team | Mati Therapeuticsmatitherapeutics.com
3. 3Partnerships | Mati Therapeuticsmatitherapeutics.com
4. 4Technology Overview | Mati Therapeuticsmatitherapeutics.com
5. 5Mati Therapeutics Inc. (United States) - Wikidatawikidata.org